SCHEMBL20568140

SCHEMBL20568140

CN(C)C(=O)c1cc(Cl)c(C#N)c(Cl)n1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ BCL6 P41182 2/20 0.39
▸ NQO2 P16083 1/20 0.39
▸ MAPK8 P45983 1/20 0.36
▸ MAPK9 P45984 1/20 0.36
▸ ALDH1A1 P00352 4/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ PDE9A O76083 2/20 0.34
▸ GPR119 Q8TDV5 1/20 0.34
▸ MALT1 Q9UDY8 1/20 0.33
▸ CNR1 P21554 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ AR P10275 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.32
▸ NCEH1 Q6PIU2 1/20 0.32
▸ TP53 P04637 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ TSHR P16473 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30692915 1.00 BCL6 (0.39) BCL6NQO2MAPK8MAPK9ALDH1A1
SCHEMBL30904726 0.80 GPR35 (0.44) BCL6L3MBTL1TSHR
SCHEMBL20569009 0.80 GPR35 (0.44) BCL6L3MBTL1TSHR
SCHEMBL20568886 0.78 MAPK8 (0.48) BCL6MAPK8MAPK9ALDH1A1GAA
SCHEMBL30692923 0.78 MAPK8 (0.48) BCL6MAPK8MAPK9ALDH1A1GAA
SCHEMBL9637797 0.70 ALDH1A1 (0.47) NQO2ALDH1A1L3MBTL1MALT1CNR1
SCHEMBL9820164 0.69 KDM4E (0.46) ALDH1A1L3MBTL1GAAKDM4EMAPT
SCHEMBL30630982 0.69 KDM4E (0.46) ALDH1A1L3MBTL1GAAKDM4EMAPT
SCHEMBL30402943 0.68 L3MBTL1 (0.40) ALDH1A1L3MBTL1GAAKDM4ETP53
SCHEMBL28287225 0.68 L3MBTL1 (0.40) ALDH1A1L3MBTL1GAAKDM4ETP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3630749-B9 2-QUINOLONE DERIVED INHIBITORS OF BCL6 CANCER RESEARCH TECH LTD (GB) 2024-05-29 — — EP disclosed
EP-4371562-A2 2-QUINOLONE DERIVED INHIBITORS OF BCL6 Cancer Research Technology Limited (GB) 2024-05-22 — — EP disclosed
EP-3630749-B1 2-QUINOLONE DERIVED INHIBITORS OF BCL6 CANCER RESEARCH TECH LTD (GB) 2024-01-10 — — EP disclosed
US-11161839-B2 2-quinolone derived inhibitors of BCL6 THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2021-11-02 — — US disclosed
US-11161839-B2 2-quinolone derived inhibitors of BCL6 THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2021-11-02 — — US disclosed
US-20210206756-A1 2-QUINOLONE DERIVED INHIBITORS OF BCL6 THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2021-07-08 — — US disclosed
US-20210206756-A1 2-QUINOLONE DERIVED INHIBITORS OF BCL6 THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2021-07-08 — — US disclosed
EP-3630749-A1 2-QUINOLONE DERIVED INHIBITORS OF BCL6 Cancer Research Technology Limited (GB) 2020-04-08 — — EP disclosed
WO-2018215798-A1 2-QUINOLONE DERIVED INHIBITORS OF BCL6 CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-11-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11161839-B2 2-quinolone derived inhibitors of BCL6 BCL6, BCL6B, BCL3 BCL6 1/4885NQO2 108/4885MAPK8 3659/4885
US-20210206756-A1 2-QUINOLONE DERIVED INHIBITORS OF BCL6 BCL6, BCL6B, BCL3 BCL6 1/4885NQO2 108/4885MAPK8 3659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback